Abstract 1963P
Background
Chordoma is a rare type of bone cancer with limited treatment options. Encouraging results showing the efficacy of pembrolizumab, a PD1 checkpoint inhibitor, in chordomas have recently been reported. Here, we performed comprehensive molecular testing to dissect the immune profile of these tumors and elucidate mechanisms of therapy response in chordomas.
Methods
Whole exome sequencing (WES) and whole transcriptome analysis was performed on samples from 14 patients (n = 6 samples from skull base, n = 8 samples from spine) with chordoma. Retrospective analysis of BostonGene’s Tumor Portrait® test results identified genomic and transcriptomic alterations of chordomas and classified tumor microenvironment (TME) subtypes according to methods from Bagaev, et al., 2021.
Results
The median age of patients was 54.5 years (range: 26-76 years). The histologic subtypes were conventional (n = 13) and dedifferentiated (n = 1). The median number of prior therapies was 1 (range: 0-3). Transcriptomic-based TME classification revealed 93% (n = 13) of patients had an immune-enriched (IE) TME subtype characterized by high levels of B cells and CD4+ T cells and low levels of tumor-associated macrophages. Only one patient had a fibrotic TME characterized by minimal immune infiltration and a high prevalence of stromal elements. High CD274 (PD-L1) expression was observed in 57% of samples. EGFR expression was high in all samples. In three cases, a 22q deletion was identified. Other clinically actionable events included SMARCB1 loss (n = 3), TP53 alteration (n = 2), BRCA1 loss (n = 1), a combination of PTEN, NF2, and TRAF2 loss (n = 1), and CDKN2A/B loss (n = 1). All samples were microsatellite stable and had low tumor mutational burden (range: 0.31-1.32 mut/Mb). From this cohort, 50% of patients were matched with at least one clinical trial based on their molecular profiles.
Conclusions
The prevalence of IE TME subtypes in chordomas supports the previously reported response to immune checkpoint inhibitors in chordomas. Together, these findings indicate next-generation sequencing could be a useful tool for informing treatment selection in advanced chordomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BostonGene, Corp.
Funding
BostonGene, Corp.
Disclosure
M. Voropaeva, I. Zhuk, A. Aukhadieva, K. Zirov, A. Makarova, L. Bednyagin: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Bagaev: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.
Resources from the same session
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15